tradingkey.logo

Regenxbio Inc <RGNX.OQ> expected to post a loss of $1.15 a share - Earnings Preview

ReutersMar 11, 2025 8:38 PM
  • Regenxbio Inc RGNX.OQ RGNX.O is expected to show a rise in quarterly revenue when it reports results on March 13 for the period ending December 31 2024

  • The Rockville Maryland-based company is expected to report a 6.9% increase in revenue to $23.754 million from $22.21 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Regenxbio Inc is for a loss of $1.15 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Regenxbio Inc is $28.50​, above​ its last closing price of $6.01. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-1.11

-1.12

-1.17

Missed

-4.3

Jun. 30 2024

-1.30

-1.29

-1.05

Beat

18.7

Mar. 31 2024

-1.29

-1.26

-1.33

Missed

-5.6​

Dec. 31 2023

-1.30

-1.27

-1.43

Missed

-12.5

​​Sep. 30 2023

-1.56

-1.52

-1.41

Beat

7.1

Jun. 30 2023

-1.43

-1.38

-1.66

Missed

-19.9​

Mar. 31 2023

-1.60

-1.54

-1.53

Beat

0.4

Dec. 31 2022

-1.24

-1.23

-1.38

Missed

-11.8

This summary was machine generated March 11 at 20:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI